Merck has announced y that it signed an agreement for Santen Pharmaceutical Co., Ltd. to purchase Merck�s ophthalmology products, Cosopt...
Merck has announced that it signed an agreement for Santen Pharmaceutical Co., Ltd. to purchase Merck�s ophthalmology products, Cosopt (dorzolamide...
Pfizer Inc. announced that REFLECTIONS B3281006, a comparative safety and efficacy study of PF-05280586 versus MabThera (rituximab-EU)/Rituxan, met its primary...
Pfizer Inc. announced that the REFLECTIONS B7391003 study, a comparative, confirmatory safety and efficacy study of PF-06439535 versus Avastin (bevacizumab),...
Indicated in the treatment of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or pseudoexfoliative glaucoma when topical beta-blocker monotherapy is not sufficient.
Pfizer announced at the American Society of Hematology Annual Meeting that the REFLECTIONS B328-06 study, a comparative safety and efficacy...
COSOPT Preservative-Free is indicated in the treatment of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or pseudoexfoliative glaucoma when topical beta-blocker monotherapy is not sufficient.
Medtronic plc, announced positive clinical trial safety and efficacy results for Sphere-360 , an investigational single-shot mapping and ablation catheter using pulsed field (PF) energy, for treatment of patients with paroxysmal atrial fibrillation (AFib)
Visus Therapeutics reported positive topline results from its Phase III pivotal BRIO-I trial for the treatment of Presbyopia. BRIO-I met the pre-specified primary study endpoints agreed upon with the US-FDA and EMA/MHRA, demonstrating contribution of elements for the once-daily, fixed-dose combination, brimochol PF, over both active comparators carbachol and brimonidine monotherapies. Brimochol PF demonstrated highly statistically significant improvements in near and distance binocular visual acuity at multiple timepoints over carbachol and brimonidine